Reach Us +1-217-403-9671
Pharmacokinetics (PK) Of Anti-tuberculosis Drug (FS-1) On Healthy Volunteers: Results From The Phase I Clinical Trial | 19789
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit

Rinat Islamov
ScientificTracks Abstracts: J Bioequiv Availab
DOI: 10.4172/0975-0851.S1.017
Introduction: FS-1 is a bactericidal and bacteriostatic drug. Starting dose of 5 mg/kg was selected based on preclinical toxicity models. The objective of the study was to characterize the PK on healthy volunteers. Methods: Three groups (n=27) of volunteers were administered single oral FS-1 in doses of 5, 10 and 15 mg/kg. Blood samples for PK were collected before and after administration at 0, 0.08, 0.17, 0.33, 0.5, 1, 2, 3, 4, 6, 12, 24, 36 and 48 h calculation of Cmax, CL, tmax, Vbeta, t1/2, MRT, AUC and k_beta. Results: Dose 5 mg/kg of FS-1: 29.6 ng/ml, 13.4 ml*h/kg, 2.5 h, 338 ml/kg, 16 h-1, 21.3 h, 340 ng*h/ml and 0.04. Dose 10 mg/ kg of FS-1: 41.0 ng/ml, 25.8 ml*h/kg, 1.6 h, 586 ml/kg, 17 h-1, 16.3 h, 402 ng*h/ml and 0.03 h-1. Dose 15 mg/kg of FS-1: 54.4 ng/ml, 24.3 ml*h/kg, 1.4 h, 536 ml/kg, 14 h-1, 15.0 h, 619.3 ng*h/ml and 0.06 h-1. Conclusion: FS-1 PK parameters were consistent with preclinical studies. Character of the relationship between the dose of the FS-1 and the AUC, as well as the constancy of FS-1 invariant PK parameters indicates that the dynamics of ADME of the drug is subject to the basic principles of linear pharmacokinetics. Values microconstants adsorption rate, interchange tissue and blood and elimination found modeling methods indicate that the ratio between their values subject to the condition: ka>k10 ≥k12, k21, suggests that the FS-1 does not tend to accumulate in tissues and organs. It also indicates a middle volume of distribution values and the relationship between drug half-life and average time of its retention.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version